Lp(a) — The Inherited Cardiovascular Risk You Should Test Once

Lipoprotein(a), pronounced "L-P little a," is an inherited cardiovascular risk factor. Roughly one in five people have elevated Lp(a), and most never find out — it is not on standard panels and it does not change with diet, exercise, or standard lipid medication. A single test establishes your lifetime baseline.

What Lp(a) physically measures

A note on naming before anything else, because it causes real confusion when people try to look up their own result. This marker is written Lp(a), LPA, or lp a depending on where you encounter it, and it is spoken as "lipoprotein little a" or simply "L-P-little-a". They all refer to the same thing: lipoprotein(a), the particle measured by this test. The one distinction worth keeping straight is that LPA in italics is also the name of the gene that determines how much of the particle you produce — so a laboratory report showing "LPA" is reporting the blood level, while a genetic report mentioning LPA is describing the gene behind it. It is also frequently confused with apo(a), which is the distinctive protein attached to the particle rather than the particle itself, and with ApoB — related, but not the same thing. Every Lp(a) particle carries one ApoB molecule, so Lp(a) is already counted inside a total ApoB result; what ApoB cannot tell you is how much of that particle count is Lp(a), which is why the two are measured separately.

An Lp(a) particle is an LDL particle with an extra protein, apolipoprotein(a), stitched onto it. That extra protein does two harmful things at once. It carries oxidized phospholipids that provoke inflammation in the artery wall, and it structurally resembles plasminogen, which interferes with the body's ability to break down clots.

A separate 2026 analysis of 35,269 UK Biobank adults found that the plasma protein signature accompanying Lp(a) still predicted coronary disease after the measured Lp(a) level was accounted for, and that it overlapped the signature of triglyceride-rich particles by 36 proteins. There is no protein test to order from that work, and it does not change how a high result here is interpreted.

So Lp(a) is both atherogenic and prothrombotic. It drives plaque and it makes a clot on that plaque more likely to persist. It is also the main lipid marker linked to calcific aortic valve stenosis, which is a distinct disease from coronary artery disease. The Suita Study followed 3,272 Japanese adults for a median of 11.5 years. Among those who developed carotid plaque, an Lp(a) at or above 50 mg/dL, set against a reading under 15 mg/dL, carried more than twice the odds of progressing to 50 percent or greater stenosis. That cohort is observational, so it does not establish that lowering Lp(a) would change the outcome.

Standard reporting vs risk thresholds

There is no single "normal range" printed the same way across labs, partly because two incompatible units are in circulation. Both are listed below.

Why lifestyle does not lower it

Lp(a) concentration is set almost entirely by the LPA gene, specifically by how many kringle IV type 2 repeats you inherited. Fewer repeats means a smaller apo(a) isoform, faster production, and higher blood levels. That is fixed at conception.

Diet, weight loss, exercise, and statins do not meaningfully change the number. This is biology, not a failure of effort. The value of the test is knowing your number, not chasing it downward.

The few things that do move Lp(a)

How and when to test

• Fasting is not required. Lp(a) is unaffected by meals, and the fasting instruction printed on the requisition form usually belongs to the lipid panel ordered alongside it.
• Ask for molar units (nmol/L) if available, since mass assays are biased by apo(a) isoform size.
• Do not test during an acute illness. Lp(a) behaves as an acute-phase reactant and rises with inflammation, infection, and after a heart attack. Wait 6–8 weeks.
• Re-test after a change in kidney function. Nephrotic syndrome can raise Lp(a) markedly, and it falls again when the condition is treated.
• Check thyroid status if a result is unexpectedly high. Untreated hypothyroidism raises Lp(a), and treatment lowers it.
• Test earlier rather than later. The result is most useful when there are decades left in which to act on it.

Distinction Between a Protein Assay and a Genetic Test

A lipoprotein(a) blood test is an immunoassay that measures protein concentration rather than DNA. For example, Labcorp test 120188 uses an immunoturbidimetric method on serum or plasma to quantify the protein concentration in the sample. The particle consists of an LDL-like core with apolipoprotein(a) attached to apolipoprotein B-100 by a single disulfide bond, as described in a 2023 review in Molecules, so the laboratory measures physical protein circulating in blood in milligrams per decilitre or nanomoles per litre rather than an individual's genetic code.

Direct DNA testing represents an entirely different category of diagnostic assay. A genetic test assesses specific inherited gene variants, similar to how an APOE4 gene test identifies specific alleles, whereas cardiovascular guidelines evaluate circulating protein concentration and do not call for an LPA genotype test. According to MedlinePlus, circulating levels remain relatively stable after early childhood and usually do not change much over time, which explains why one lifetime measurement of the protein concentration is usually sufficient in clinical assessments without ordering genetic sequencing.

This distinction also separates Lp(a) testing from a separate lipid diagnosis, familial hypercholesterolemia, which relies on its own established diagnostic criteria rather than an Lp(a) result. The 2022 European Atherosclerosis Society consensus statement notes that routine correction of LDL-C for Lp(a)-derived cholesterol is not recommended due to high variability, with a possible exception when diagnosing familial hypercholesterolemia where a high Lp(a) concentration can make an LDL-C reading harder to interpret. Across routine cardiovascular evaluations, the clinical blood draw remains an immunoassay measuring circulating protein rather than a genetic readout.

Reasons for Omission from the Standard Lipid Panel

Lipoprotein(a) remains absent from standard blood panels because major cardiovascular guidelines disagree on whether to screen the general population or restrict testing to high-risk clinical presentations. The first consensus panel from the European Atherosclerosis Society in 2010 recommended selective screening only for individuals at intermediate or high cardiovascular risk. That panel prioritized patients with premature cardiovascular disease, familial hypercholesterolaemia, or recurrent events despite statin therapy. The 2018 AHA/ACC multisociety cholesterol guideline maintained this targeted model by classifying an elevated concentration as a risk-enhancing factor. It noted a relative indication for measurement in patients with a family history of premature disease rather than recommending routine universal screening. In direct contrast, the 2019 ESC/EAS dyslipidaemia guidelines recommended that lipoprotein(a) measurement should be considered at least once in each adult person's lifetime. The 2022 European Atherosclerosis Society consensus statement reinforced that position by recommending routine measurement as part of an initial lipid profile to identify high cardiovascular risk. In the United States, the National Lipid Association 2024 focused update also shifted from selective testing to a universal position. It concluded that sufficient evidence supports measuring levels at least once in every adult for risk stratification, noting that elevated levels occur in about one of five individuals. As summarised by Reyes-Soffer and colleagues in 2024, this international split between universal lifetime testing and targeted indications remains the defining disagreement across clinical bodies.

Published clinical registry data show that this guideline debate leaves testing rates near zero across the United States. In an analysis of the TriNetX research network covering 70,820,858 adults across 48 healthcare organisations between 2015 and 2024, Bansal and Cho found that only 0.1% of patients in that US cohort had ever received a lipoprotein(a) test. Even among clinical subgroups meeting criteria for selective screening, testing remained rare:

• 0.75% in premature atherosclerotic cardiovascular disease
• 3.52% in familial hypercholesterolaemia
• 0.85% in people aged 50 or younger after a heart attack
• 0.42% in aortic stenosis
• 0.19% with a documented family history

Among the small fraction tested, 21.4% had an elevated concentration. A separate nationwide US study by Ramsis and colleagues examined approximately 300 million medical records between 2015 and 2024. They identified 728,550 tested individuals, which represents roughly 0.2% of patients over the decade. While annual testing in that US cohort rose from 0.03% in 2015 to 0.24% in 2024, the absolute numbers confirm that testing has reached only a fraction of the population. Single-system studies show the same pattern. An analysis by Manzato and colleagues at the Mayo Clinic found that among 257,225 US patients who received a lipid panel, only 0.15% had lipoprotein(a) measured within a year and 0.94% had ever been tested. The authors concluded that the marker is undertested even at tertiary referral centers. Similarly, a Northern California study by Brar and colleagues at Sutter Health recorded an overall testing rate of 1.0% across 1,484,410 individuals between 2010 and 2021.

Documented clinical barriers explain why laboratory orders remain so infrequent despite high population prevalence. A review by Rendler, Murphy, and Yeang identified five structural obstacles:

• limited recognition of the causal evidence base
• the clinician assumption that testing would not alter clinical management
• waiting for outcome trials of targeted therapies
• confusion caused by conflicting measurement units
• cost concerns

Furthermore, a standard lipid panel cannot isolate lipoprotein(a) particles because of basic biochemical constraints. The 2022 European Atherosclerosis Society consensus statement explains that cholesterol contained in lipoprotein(a) particles cannot be separated from that in LDL particles on routine assays, so it is collectively reported as LDL-C concentration. While historical models assumed that cholesterol accounted for 30% to 45% of total lipoprotein(a) particle mass, direct measurements cited in the statement revealed that the actual proportion ranges from 6% to 60% across individuals. Because of that broad variation, the panel does not recommend routine mathematical correction of LDL-C for lipoprotein(a) cholesterol.

The assay itself is the second reason lipoprotein(a) sits outside a general chemistry panel. Unlike an apolipoprotein B test or standard cholesterol panel, measuring lipoprotein(a) requires detecting apolipoprotein(a), which varies widely in physical size between individuals. The kringle IV type 2 repeat count described above ranges from 3 to 40 copies, with fewer than 23 defining a small isoform. The 2022 European Atherosclerosis Society consensus statement notes that this polymorphism explains 30% to 70% of the variability in concentration. Most commercial clinical laboratories use polyclonal antibodies that bind to these repeated kringle sections. Because larger isoforms carry more repeated binding sites, polyclonal assays tend to overestimate levels in individuals with large isoforms and underestimate them in people with small isoforms. The consensus statement emphasizes that clinical assays should ideally use antibodies directed against a unique, non-repetitive epitope that binds each particle once and reports results in molar units (nmol/L).

Isoform size is the reason the two units cannot be converted: the mass-to-particle ratio differs from one person to the next. The 2022 European Atherosclerosis Society consensus panel explicitly advises against using a standard factor to convert between mg/dL and nmol/L, noting that a factor between 2 and 2.5 is only a best guess. Global laboratory standardisation remains unresolved. In a review of lipoprotein testing, Miida observed that while international reference material SRM 2B was distributed to manufacturers, global standardisation of immunoassays was not achieved because different commercial antibodies target different epitopes. The International Federation of Clinical Chemistry has endorsed an isoform-independent reference measurement procedure using mass spectrometry, but that remains a specialized reference tool rather than a routine hospital test. In their US cohort analysis, Ramsis and colleagues found that 64.2% of tests in 2024 were reported in molar units, leaving more than a third of tests in mass units that cannot be reliably converted.

Repeat Testing Guidelines and Changes Across Menopause

Because the level is genetically fixed, clinical guidelines treat a single adult measurement as definitive. According to the 2022 European Atherosclerosis Society (EAS) consensus statement, circulating levels range from under 0.1 mg/dL to over 300 mg/dL (less than 0.2 to 750 nmol/L). Full gene expression occurs by age 2, and adult concentrations typically establish around age 5.

Levels can still climb through adolescence. For youth presenting with ischaemic stroke or a family history of premature atherosclerotic cardiovascular disease (ASCVD), the EAS statement recommends testing and notes that multiple measurements may be required before adulthood. For typical adults, the consensus concluded that repeat testing does not improve risk prediction, with the illness-related exceptions already listed above.

That lifetime testing policy faces growing pushback regarding women. In a 2024 study in the American Journal of Preventive Cardiology, Corral and colleagues observed that female lipoprotein(a) levels remain stable until perimenopause and rise thereafter. The authors concluded that this post-menopausal rise challenges the single-measurement strategy, encouraging re-evaluation after the menopause transition.

European practice guidelines have formally responded. The 2025 Focused Update of the ESC/EAS dyslipidaemia guidelines in the European Heart Journal restates that measurement should be considered at least once in every adult's lifetime, but notes that levels may rise after menopause. The update describes a second measurement after menopause as reasonable, particularly when pre-menopausal values were borderline.

In the 2025 STAR-Lp(a) study, Burzynska and colleagues evaluated 1,263 patients (68.7% women, median age 69) retested across one to three year intervals. The median change was 16.7% (interquartile range [IQR] 6.5% to 33.3%), with 64.7% of patients shifting by at least 10% from baseline, 44.3% by at least 20%, 28.2% by at least 30% and 14.0% by at least 50%.

The investigators concluded that these variations make the once-in-a-lifetime stance inaccurate and argued it should be revised. However, 93.8% of patients remained in their baseline risk category, with 3.1% reclassifying higher and 3.1% lower.

No guideline specifies a repeat testing interval in years for adults. That holds across consensus statements from the EAS, the American College of Cardiology (ACC), the American Heart Association (AHA), and the 2024 National Lipid Association (NLA) focused update. No guideline cites randomised trial evidence demonstrating that repeating lipoprotein(a) testing improves clinical outcomes.

The 2022 EAS position against routine retesting relies on statistical risk prediction equations rather than randomised outcome trials. A perimenopause biomarker panel tracks the broader metabolic shifts across that transition, but no trial evidence shows that repeating lipoprotein(a) itself improves outcomes.

What to do if Lp(a) is elevated

• Tighten the ApoB target. When one risk factor cannot be lowered, the standard response is to lower every other one further — usually to an ApoB under 65 mg/dL.
• Consider a coronary calcium score. It converts an inherited statistical risk into a measurement of what has actually happened in your arteries.
• Screen first-degree relatives. Lp(a) is autosomal codominant, so parents, siblings, and children each have roughly a 50% chance of sharing the elevation.
• Control blood pressure and stop smoking. Both multiply Lp(a)-associated risk rather than merely adding to it.
• Ask about echocardiography over time if there is any murmur, given the aortic valve association.
• Do not start niacin for this. It lowers the number without improving outcomes, and it carries real side effects.

What it means in combination

• High Lp(a) + familial hypercholesterolemia: the highest-risk lipid combination in clinical practice. This belongs with a lipid specialist.
• High Lp(a) + high ApoB: two atherogenic exposures stacked. Aggressive ApoB lowering is the available lever.
• High Lp(a) + high hsCRP: particles plus an inflamed vessel wall. Lp(a) carries oxidized phospholipids, so the two are mechanistically linked.
• High Lp(a) + a calcium score of zero at 55: genuinely reassuring in the near term. It supports continued prevention rather than escalation.
• High Lp(a) + LDL-C stuck above target on a maximal statin: the Lp(a) cholesterol contribution described above. Correct the target rather than the drug.
• High Lp(a) + a family history of early heart attack: often the explanation for that history. Test the relatives.

When a result warrants seeing a physician

• Lp(a) above 125 nmol/L (50 mg/dL), particularly under age 50 when there is the most time to act.
• Any result above 250 nmol/L, which warrants specialist lipid input and family cascade screening.
• Elevated Lp(a) with a first-degree relative who had a heart attack or stroke before 55 in men or 65 in women.
• Elevated Lp(a) with a known heart murmur or diagnosed aortic valve disease.
• Any chest pain, exertional breathlessness, or new exercise intolerance — that is urgent and independent of the number.

Related

• ApoB — the primary lipid risk marker
• hsCRP — inflammation load
• Normal vs optimal ranges
• Lp(a) test cost — what the test costs cash, and why Medicare excludes it as screening
• Doctor-led longevity programs compared